Evaluation of medication adherence of weekly DPP-4 inhibitor, trelagliptin in treating of type 2 diabetes mellitus

Evaluation of medication adherence of weekly DPP-4 inhibitor, trelagliptin in treating of type 2 diabetes mellitus - Medication adherence of trelagliptin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025939

Enrollment

Registered

2017-02-01

Start date

2017-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women who were diagnosed with type 2 diabetes mellitus 2.Patients have been taking daily DPP-4 inhibitors for more than 12 weeks

Exclusion criteria

Exclusion criteria: 1.type1 diabetes mellitus 2. Past history of diabetic ketoacidosis, diabetic coma, or bofore coma 3.Severe infection, before and not long after surgery, or patient with severe trauma 4 .Severe liver dysfunction 5.Women with during pregnancy , nursing, or pregnant likelihood 6.Inadequte patient judged by doctor

Design outcomes

Primary

Measure	Time frame
Amount of change in medication asherence after administration 24 weeks later	—

Secondary

Measure	Time frame
HbA1c Body weight Serum lipid Urinary albumin excretion Urinary L-FABP excretion, serum cystatinC,eGFR	—

Countries

Japan

Contacts

Public ContactHajime Koyano

Juntendo University Urayasu Hospital Endocrinology and Diabetology

koyano@juntendo-urayasu.jp047-353-3111

Outcome results